Micro
Emerging
Active
Sanara MedTech Inc. Q4 2025 record revenue from hybrid commercial model
New narrative with limited coverage — still forming.
Score
0.2
Velocity
▲ 0.0
Articles
4
Sources
1
Top Movers
| Ticker | Sector | Change |
|---|---|---|
| Health Care | +32.7% |
Sentiment Timeline
Sector Performance
Event Timeline
Top Movers
| Ticker | Sector | Change |
|---|---|---|
| Health Care | +32.7% |
🤖
AI Overview
Sanara MedTech Inc. Q4 2025 record revenue from hybrid commercial model
What happened: Sanara MedTech Inc. reported record Q4 2025 revenue of $103.1 million, up 19% year-over-year, driven by a hybrid commercial model combining field sales and independent distributors. Sanuwave Health, a subsidiary, contributed significantly with Q4 revenue of $13.4 million, a 30% increase, and record system placements—624 UltraMIST systems sold in 2025.
Market impact: The medical device sector is positively affected, with investors attracted to Sanara's hybrid commercial model, which drives growth and profitability. Sanuwave's record sales and industry disruption potential, as indicated by the introduction of a new active system metric, further boosts confidence.
What to watch next: Sanara's Q1 2026 earnings call on April 25, 2026, will provide updates on the hybrid commercial model's performance and Sanuwave's growth trajectory. Additionally, investors await the FDA's decision on Sanuwave's 510(k) submission for the UltraMIST system, expected by June 2026.
What happened: Sanara MedTech Inc. reported record Q4 2025 revenue of $103.1 million, up 19% year-over-year, driven by a hybrid commercial model combining field sales and independent distributors. Sanuwave Health, a subsidiary, contributed significantly with Q4 revenue of $13.4 million, a 30% increase, and record system placements—624 UltraMIST systems sold in 2025.
Market impact: The medical device sector is positively affected, with investors attracted to Sanara's hybrid commercial model, which drives growth and profitability. Sanuwave's record sales and industry disruption potential, as indicated by the introduction of a new active system metric, further boosts confidence.
What to watch next: Sanara's Q1 2026 earnings call on April 25, 2026, will provide updates on the hybrid commercial model's performance and Sanuwave's growth trajectory. Additionally, investors await the FDA's decision on Sanuwave's 510(k) submission for the UltraMIST system, expected by June 2026.
AI Overview as of Apr 23, 2026
Timeline
First SeenMar 27, 2026
Last UpdatedMar 27, 2026